Projet EN_ACTI2NG (Horizon 2020, appel à projets 2016)
Action : Doctoral Networks
Panel : Life Sciences
Statut du projet : CLOSED

The EN-ACTI2NG program (European Network on Anti-Cancer Immuno-Therapy Improvement by modification of CAR and TCR Interactions and Nanoscale Geometry) emanates from the recent clinical evidence that T cells expressing engineered tumor-specific immune receptors can eradicate certain tumors that do not respond to conventional treatment. To obtain T cells with reactivity to a wider array of tumors and to improve efficiency and on- and off-target toxicity are current challenges Therefore the EN-ACTI2NG program aims 1) to train PhD students with expertise in development of new and improved T cell-mediated cancer immuno-therapies; 2) to endow the PhD students with the ability to establish efficient communication between the academic and industrial research environments and between scientists and the general public; 3) to improve T cell mediated anti-cancer immuno-therapy by the identification and development of new cancer-specific immune receptors and enhancing their function by identifying and modifying their molecular mechanism of action. To reach these objectives we have designed individual research projects ranging from biophysical analysis of immune receptors, via molecular modification of their structure and testing their tumor killing capacity in cell-based and pre-clinical assays to product development. Secondments will assure that each PhD student will be exposed to these complementary approaches and that there will be synergic feedback between the projects, producing innovative results that could otherwise not be achieved. Extensive training in research-specific skills, career development and a continuous training in communication skills will allow the PhD students to become facilitators of the process of transformation of scientific innovation into products with social and economic value. As such, the EN-ACTI2NG program should contribute to overcoming the more general challenge of converting the European Community into an innovation-driven society.

Mots clés : chimeric antigen receptors, t cell receptor, tumor specific t cells, translational immunology, biochemistry of signaling, receptor clustering, super resolution fluorescence microscopy

Participants :
- Medical University of Vienna (Autriche) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 255934.08 €
- University Hospital Würzburg (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 249216.48 €
- Stratec consumables gmbh (Autriche) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 255934.08 €
- University of Navarra (Espagne) — Partner, beneficiary, Recherche, subvention : 247872.96 €
- University Hospital Regensburg (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 186912.36 €
- TU Wien (Autriche) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 255934.08 €
- Sony Digital Audio Disc Corporation (Austria) (Autriche) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 0.0 €
- Leiden University Medical Center (Pays-Bas) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 255374.28 €
- University of Bristol (Royaume-Uni) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 273287.88 €
- University of Freiburg (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 249216.48 €
- University Hospital Cologne (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 62304.12 €
- Spanish National Research Council (Espagne) — Coordinator, beneficiary, Recherche, subvention : 247872.96 €
- Scienseed sl (Espagne) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Instil bio (uk) limited (Royaume-Uni) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €